The companies will use Luminex's xMAP technology to develop an automated biothreat detection tool for a US biosecurity network.
The companies will co-develop and co-market ion channel genes for mammalian cell line research.
The companies will use Cellzome's Episphere chemical proteomics technology to identify candidates for anti-inflammatory drugs. If certain milestones are met, Cellzome could potentially receive €475 million.
Following a scientific data review, ExonHit Therapeutics and BioMerieux have decided to discontinue their colon cancer collaboration.
The company will work with Semmelweis University to develop micromethods for handling small biosamples for microarray analysis.
23andMe and Airbnb have partnered to offer "heritage travel," according to Venture Beat.
China may include regulations protecting genes and embryos in its update of its civil code, Nature News reports.
In Nature this week: exome sequence analysis of individuals with type 2 diabetes, genomic prediction of maize yield across environments, and more.
NPR reports on efforts to engineer bacteriophages to destroy antibiotic-resistance bacteria.